Elevating the voice of the patient to accelerate the development and launch of new treatments.
Developing better medicines starts with the people they're for
The evidence is clear: medicines are more likely to succeed when patients help shape the decisions behind them.
Yet patient engagement is still treated as a late-stage activity - something to document for regulators rather than embed throughout development. As a result, many teams make critical decisions without understanding the realities of the people who will ultimately use their products.
The consequences are predictable. Clinical trials recruit more slowly, or not at all. Regulators identify issues that could have been addressed earlier. Products reach the market with unnecessary treatment burden or experiences that fail to fit into patients' lives.
These aren't unpredictable risks. They're the consequence of a gap between what the industry knows and how it operates.
Our team brings together deep domain expertise from life sciences and technical depth from leading AI companies to bridge that gap.
Our mission
We help life science companies build stronger partnerships with patient communities to accelerate development and access to new treatments.
Axcela Bio provides a single operating system for patient engagement and patient advocacy - helping teams find the right patient communities, manage engagements, capture patient insight, and connect what they learn to R&D, regulatory and commercial decisions.
By making patient community intelligence and insights accessible, traceable, and actionable, we help organizations move beyond patient engagement as a compliance activity and toward patient partnership as a strategic advantage.
Better for patients. Better for innovators. Better medicines, delivered faster.